Analyst issues $6 dollar price target on Neptune Print E-mail
By Staff and Wire Reports   
Tuesday, 17 May 2011 09:32

Our premium subscribers first heard about this stock when it was trading at the $2.32 mark a few weeks ago. Now we're hearing that more institutional buying and high profile firms are getting ready to take positions. That, in-turn, should lead to even more buying by retail investors. It's the stock snowball and visibility effect and this company deserves it.


“BUY” sums up in one word the conclusions by Versant Partners analyst, Doug Loe, in an exhaustive, 87-page initiating coverage report on Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) (TSX-V:NTB) and a small report on its 60% owned subsidiary, Acasti Pharma (TSXV: APO.V).

Of meaning to investors and those watching the company is his one-year target price of $6 dollars on Neptune and $3 dollars on Acasti Pharma.

NTB’s May 16th closing price was $3.09 +0.09 (3.05%) and Acasti was unchanged at $1.05.

Promising results from Amarin Corporation's (Nasdaq: AMRN ) new cholesterol drug have helped call attention to Neptune, which is aiming for cholesterol/hyperlipidemia's ultimate prize, but unlike most companies dealing with clinical studies and regulatory approvals, Neptune is a revenue generating company whose products are already marketed and distributed in over 20 countries worldwide.

The Versant Partners’ report, subtitled: “Krill oil franchise poised to outperform in multiple consumer and medical markets” features a few key points of note.

With NEPT’s fiscal year end being February, Mr. Loe is calling for:

* F2012 revenues of $21.79 million and earnings $4.34 million ($0.09 EPS)
* F2013 revenues of $32.39 million and earnings of $8.81 million ($0.17 EPS)
* F2014 revenues of $45.37 million and earnings of $15.69 million ($0.30 EPS)
Loe cited management plans to meet forecasted demand by increasing current plant production from 130 thousand kilograms of krill oil per year to 430 thousand kilograms per year by 2015, a 300% production increase.
The report pinned its share price targets not only on the business Neptune has in hand, but also its future. By far, the biggest foundation Mr. Loe constructed on which to base his conclusions came from his meticulous research into the product itself – Neptune Krill Oil or NKO as it is branded on the market - and all its further refined products, such as Acasti’s drug candidate called ‘CaPre’.

Along the way, Loe also gives a significant nod to the functional food alliances Neptune developed with Yoplait – which is 50% owned by General Mills – and the food manufacturing behemoth, Nestle.

Mr. Loe wrote that both Yoplait and Nestle “should conclude development,” of their research into Neptune Krill Oil by the end of the current year and that assuming all goes well, the sales of krill-oil infused food products by these giants would be a major revenue driver for Neptune in 2013/14.

A very recent financing has left Neptune with an estimated $17.6 million in the bank and total debt of $5 million.  On Friday,  Neptune announced that it has closed the second portion of its oversubscribed private placement financing which was announced on May 3rd.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets.

NEPT stock ran to as high as $3.95 recently before some profit taking (and completely clueless bashing by shorts who take massive positions in the stock before issuing their "trade like me" alerts) pulled the price back. Despite all of that Monday's closing price was up 2.65% to $3.10 +0.08. 

Disclosure: None

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus